Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
| Autor: | Mark A. Wainberg |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Epidemiology
Human immunodeficiency virus (HIV) Review Dermatology Drug resistance medicine.disease_cause Emtricitabine rilpivirine resistance chemistry.chemical_compound Virology Medicine In patient human immunodeficiency virus treatment Reverse-transcriptase inhibitor business.industry Health Policy RC581-607 non-nucleoside reverse transcriptase inhibitors Regimen Infectious Diseases chemistry Rilpivirine Immunologic diseases. Allergy business Viral load medicine.drug |
| Zdroj: | HIV/AIDS (Auckland, N.Z.) HIV/AIDS: Research and Palliative Care, Vol 2013, Iss default, Pp 41-49 (2013) |
| ISSN: | 1179-1373 |
| Popis: | Mark A WainbergMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, CanadaAbstract: A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non-nucleoside reverse transcriptase inhibitor. This review focuses on the clinical utility of rilpivirine in terms of efficacy and virologic suppression, drug resistance, drug-drug interactions, and safety. The rilpivirine-tenofovir-emtricitabine combination is a safe and effective regimen for use in most patients who are ready to start first-line anti-human immunodeficiency virus therapy. Although drug resistance can be a problem in patients who initiate therapy on rilpivirine-based regimens with viral loads > 100,000 copies of viral RNA/mL, this problem can be alleviated by first starting therapy with efavirenz-tenofovir-emtricitabine for several months to suppress viral load to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|